Summary Having regard to the recent decision of Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis) 2023 FCAFC 97, pharmaceutical originator patentees seeking to prevent the entry of a generic drug into the Australian market through a preliminary injunction, need to be aware that the Australian Government has a right to seek “market-size damages” from the […]
Australia: Patent Box – Expansion to Agricultural and Low Emissions Innovations
In its Budget 2022-23, the Australian Government announced major expansions to the proposed ‘Patent Box’ scheme providing concessional tax treatment to eligible income for Australian corporate taxpayers. The Government will now expand the scheme to support innovations in the Australian agricultural sector, specifically: In addition, the Government will provide concessional tax treatment for corporate taxpayers […]
Australia: Introduction of Patent Box Tax Concessions for Australian Medical and Biotechnology Innovations
In a boost for Australian-based medical and biotechnology innovators, the Australian Government has announced the introduction of a ‘Patent Box’ scheme in its Budget 2021-2022. Whilst the Government will consult with industry before finalising the details of the Patent Box, features are expected to address the following: (a) With effect from 1 July 2022, a […]
Australian Patent Case Law Snap Shot
Sequenom, Inc. v Ariosa Diagnostics, Inc. [2019] FCA 1011 (27 June 2019)[1] A recent Federal Court of Australia decision held that methods of medical diagnosis are clearly patentable subject matter in Australia. The Federal Court of Australia has taken the opposite position as compared to the corresponding litigation in the United States of America. [2] The main […]
Australian Patent Case Law Snap Shot
Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty Ltd) [2019] FCA 28 (22 January 2019) A recent Federal Court of Australia decision held that in order for a party to infringe a Swiss-style claim the alleged infringer must manufacture the medicament with the objective intention to […]